Sanyal 2024 — Retatrutide MASLD Study

New England Journal of Medicine·June 8, 2024

Sanyal AJ, et al.

Summary

Triple agonist retatrutide showed promising results in metabolic dysfunction-associated steatotic liver disease.

Study Details

Study Design

Phase 2 randomized, double-blind, placebo-controlled trial

Indication

MASLD/MASH with fibrosis

Intervention

Retatrutide vs placebo

Species

Human

Risk of Bias Assessment

Lilly-sponsored